Biotechnology, Pharmaceuticals

Join the 4th edition of BioFit on December 1st & 2nd 2015 in Strasbourg, France +1 day SPECIAL INVITATION to a Franco-German-Swiss Excellence Event on November 30th.

Romain LONCHAMBON - 04-nov.-2015 13:50:01

  BIOFIT is the leading business convention in Europe for open Innovation, technology transfer and collaborative research in Life Sciences. More than 1300 participants will attend the 2015 edition, which will be held in Strasbourg (Alsace region), at the heart of the Franco-German-Swiss BioValley Cluster, a center of excellence for therapeutic innovation I www.biofit-event.com   Public & Private collaborations   BioFIT is the leading partnering event in Europe for Open Innovation, technology transfer and collaborative research in the field of Life Sciences, with the highest attending rate of academia, TTOs and research institutes together with big pharma, emerging and small biotech companies, medtech and diagnostics companies.   Engage new partnerships Foster the emergence of collaborative projects Intensify the flow of licenses in the field of life sciences   Who will you meet?   The event gathers leaders from pharma, biotech, medtech, IVD companies, investors, as well as professionals from technology transfer and academia.   Website : http://www.biofit-event.com/   Registration for Biofit : http://www.biofit-event.com/registration/registration-fees/  


Four French suppliers met the decision-makers and the Cameroonian influencers

Aurélien NEU - 27-mai-2014 14:06:59

  Four French suppliers of healthcare solutions (medical imaging, furniture and systems of sterilization and laundries) met the decision-makers and the Cameroonian influencers, to Douala and Yaoundé. 47 meetings (appointment) B to B wereorganized. The participants also visited two major public hospitals, currently driving innovative projects of renovation and extension. The projects-managers expressed an immediate interest for the solutions proposed by the French companies. The French offensive arrives at the convenient moment for the local buyers, marked by the launch of important programs of investments and a real will to rebuild the cooperation with the historic suppliers, French one particular, while the last ten years had rather been favorable to the Asian offers. Moreover, certain participants booked orders or identified by the partners during the mission.


The Healthcare and Medical Technology Industry in : Overview of a sector of excellence

Aurélien NEU - 27-mai-2014 14:01:01

  The healthcare industry is a key partner for governments in anticipating and providing solutions geared towards protection, prevention, diagnostics, compensating for disabilities, treatment and improving the daily quality of life of health product users. It plays a critical role in public health, one of the principal challenges facing French society. The healthcare industry (much like the aerospace and luxury sectors) plays a crucial part in preserving France’s industrial base and represents a major comparative advantage for the French economy: it employs more than 200,000 people directly and over 500,000 indirectly, and continues to go from strength to strength. The relative importance of the sector within France’s industrial landscape is greater than in other European economies of a similar size. Source : http://www.invest-in-france.org/us Further information : About French companies > Medical device and Healthcare


Biotechnology in France

Aurélien NEU - 24-avr.-2014 14:37:25

  When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America.   French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!”   An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe. www.ubifrance.com/french-exporters-directory/companies.aspx


About
Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For further information, please visit: www.businessfrance.fr Saudi Arabia: Business France has two offices in KSA : the Head Office in Riyadh (within the French embassy), and a branch in Jeddah (within the French Consulate). Business France in Saudi Arabia supports between 100 and 150 French companies each year, through individual

read more :

Facebook
Press area & Media Gallery :